期刊文献+

^(99)Tc^m-EIDP的制备及生物学分布 被引量:9

The preparation and biodistribution of ^(99)Tc^m-EIDP
下载PDF
导出
摘要 本文探讨99Tcm标记2-(2-乙基-咪唑-1-基)-1-羟基乙烷-1,1-双膦酸(EIDP)用于骨显像的可能性。以2-乙基咪唑为原料,经3步反应制得EIDP。以SnCI2为还原剂,制得99Tcm-EIDP。正常小鼠尾静脉注射1.0MBq(0.2mL)99Tcm-EIDP,取不同时间处死小鼠的心、肝、脾、肺、肾、肌肉、骨和血,测量放射性,计算每克组织百分注射剂量率(%ID/g)及骨中放射性与各组织中放射性的比值,并计算血药清除动力学方程和各参数。新西兰兔静脉注射99Tcm-EIDP后于不同时间显像。EIDP的制备总收率为35.5%。99Tcm-EIDP的标记率和放化纯均>95%。在注射99Tcm-EIDP1h后小鼠骨摄取99Tcm-EIDP的量达到最大值Am骨为23.76%ID/g,Am骨/Am血为33.94,Am骨/Am肌肉为95.04。血药动力学方程为C=1090.736e-6.982t+84.956e-0.379t。兔显像结果表明,2h时即可获得清晰的兔骨显像图。99Tcm-EIDP制备方便,骨显像清晰,是一种较有潜力的新型骨显像剂。 To evaluate the feasibility of ^99Tc^m-2-(2-ethylicimidazol-1-yl)-1-hydroxyethane-1,1-diphosphonic acid (EIDP) as a bone imaging agent, EIDP was synthesized by three-step reactions from 2-ethylicimidazol and ^99Tc^m-EIDP was prepared with SnCI2 in 10 min at room temperature. Normal mice were injected intravenously with 1.0 MBq ^99Tc^m-EIDP of 0.2 ml and sacrificed at different phase after injection. Samples of heart, liver, spleen, lung, kidney, muscle, bone and blood were taken for uptake (in %ID/g) measurement, and the bone-to-organ uptake ratios were calculated. The blood clearance kinetics was calculated, too. Bone imaging was performed in normal rabbit after intravenous injection. The total yield for the preparation of EIDP was 35.5%. Both the labeling yield and radiochemical purity of ^99Tc^m-EIDP were over 95%. The bone uptake is up to 23.76 %ID/g at lh after the injection. The bone-to-blood and bone-to-muscle uptake ratios were 33.94 and 95.04, respectively. The kinetics equation was: C= 1090.736e^-6.982t + 84.956e^-0.379t, and the initial half life and late half life were 4.76 and 105.5 rain respectively. A clear bone imaging of rabbit was obtained 2h after injection. The ^99Tc^m-EIDP, which can be prepared conveniently, exhibited high uptake in bone and would be a potential bone imaging agent.
出处 《核技术》 EI CAS CSCD 北大核心 2008年第9期698-701,共4页 Nuclear Techniques
基金 吴阶平医学基金会临床科研专项基金资助(320.6750.00615)
关键词 ^99Tc^m-EIDP 动物实验 药代动力学 骨骼 放射性核素显像 ^99Tc^m-EIDP, Animals experiment, Pharmacokinetics, Skeleton, Radionuclide imaging
  • 相关文献

参考文献5

  • 1Herbert. Endocrine Reviews, 1998, 19(1): 80-100
  • 2Dawson N A. Expert Opin Phamacother. 2003, 4: 705-716
  • 3Vasireddy S, Talwarkar A, Miller H, et al. Clin Rheumatol, 2003, 22:376-380
  • 4罗世能,王洪勇,谢敏浩,刘晓亚,叶万忠,陈志明,冯瑛瑛,曹国宪.~99Tc^m-MIDP的制备及其生物学分布[J].中华核医学杂志,2005,25(6):341-343. 被引量:11
  • 5GUO Xuehua, LUO Shineng. Nuclear Science and Techniques, 2006, 17(5): 285-288

二级参考文献5

  • 1Jaeggi-Knut A, Widler L. Substituted alkanediphosphonic acid and pharmaceutical use. United States Patent 4939130. 1990-07-03.
  • 2Cheer SM, Noble S. Zoledronic acid. Drugs, 2001, 61 : 799-805.
  • 3Luo SN, Wang HY, Xie MH, et al. The preparation of ^99Tc^m-zoledronate. 5th International Conference on Isotopes, Brussels, 2005. 21.
  • 4Fleisch H. Bisphosphonates: mechanisms of action. Endocr Rev,1998, 19: 80-100.
  • 5刘丽琴,杨建权,李晔,李至敏,王学斌.一种新型骨显像剂^(99m)TcAMDP的初步研究[J].北京师范大学学报(自然科学版),2003,39(2):230-234. 被引量:8

共引文献10

同被引文献87

引证文献9

二级引证文献6

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部